Clinical outcomes after reirradiation with dose painting of recurrent or second primary head and neck cancer
5 affiliations
- 1Department of Oncology, Oslo University Hospital , ,
- 2Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust , ,
- 3Department of Medical Physics, Oslo University Hospital , ,
- 4Department of Nuclear Medicine, Innlandet Hospital Trust , ,
- 5Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital , ,
Abstract
Purpose: Recurrent or second primary head and neck cancer (rsHNC) presents a radiotherapeutic challenge due to limited tolerance of previously irradiated tissues. These patients could benefit from dose painting (DP), which focuses on delivering maximal dose to areas of high tumor burden while respecting dose constraints to organs at risk. In this study, we compare clinical outcomes in one group receiving standard reirradiation with a group receiving 18F-fluorodeoxyglucose (FDG) PET/CT-guided DP.
Methods: Our standard reirradiation regimen is hyperfractionated radiotherapy (RT) of 1.5 Gy x 40 (60 Gy total dose). For DP, we defined two FDG-based prescription volumes receiving at least 65 Gy and 70 Gy. Thirteen patients receiving standard RT were compared with 10 DP patients. Toxicity was scored using CTCAE v3.0. Disease-related endpoints were locoregional control (LRC), disease-free survival (DFS) and overall survival (OS).
Results: The mean composite toxicity score was maximal at the end of RT, with varying patterns across the CTCAE items. No significant difference in toxicity was found between the groups except for dysphagia at 6 months, where the standard RT group had worse scores (p=0.01). No differences were found in LRC and DFS. Two-year OS was 50% in the DP group versus 15% in the standard group (p=0.04), although this may reflect higher comorbidity in the standard group.
Conclusion: DP of rsHNC did not increase toxicity compared with standard reirradiation. No evidence of improved disease control was found. However, DP may benefit selected patients, and future studies should focus on identifying these candidates.
Clinical trial registration: https://clinicaltrials.gov , identifier NCT02921581.
Related
- Can future reirradiation justify upfront proton therapy? An extension of model-based proton therapy selection beyond primary-course NTCP benefit
- Real-Time Plasma State Prediction via FPGA-Accelerated Quantized Recurrent Probabilistic Neural Networks
- Learning-Induced Dynamical Transition in Recurrent Neural Networks
- Graph-Recurrent Learning of Emergent Collective Dynamics
- Non-Polynomial Wave Computation through Recurrent Resonant Scattering
BibTeX
@article{dale2026clinical,
title = {{Clinical outcomes after reirradiation with dose painting of recurrent or second primary head and neck cancer}},
author = {Einar Dale and Morten E. Evensen and Cecilie D. Amdal and Torbjørn Furre and Jon M. Moan and Liv Cathrine Heggebø and Ayca M. Løndalen and Eirik Malinen},
journal = {Frontiers in oncology},
year = {2026},
month = sep,
doi = {10.3389/fonc.2026.1966123},
url = {https://europepmc.org/article/PMC/PMC13661507},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical outcomes after reirradiation with dose painting of recurrent or second primary head and neck cancer
AU - Einar Dale
AU - Morten E. Evensen
AU - Cecilie D. Amdal
AU - Torbjørn Furre
AU - Jon M. Moan
AU - Liv Cathrine Heggebø
AU - Ayca M. Løndalen
AU - Eirik Malinen
PY - 2026
DA - 2026/09/30
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1966123
UR - https://europepmc.org/article/PMC/PMC13661507
AB - Purpose: Recurrent or second primary head and neck cancer (rsHNC) presents a radiotherapeutic challenge due to limited tolerance of previously irradiated tissues. These patients could benefit from dose painting (DP), which focuses on delivering maximal dose to areas of high tumor burden while respecting dose constraints to organs at risk. In this study, we compare clinical outcomes in one group receiving standard reirradiation with a group receiving 18F-fluorodeoxyglucose (FDG) PET/CT-guided DP. Methods: Our standard reirradiation regimen is hyperfractionated radiotherapy (RT) of 1.5 Gy x 40 (60 Gy total dose). For DP, we defined two FDG-based prescription volumes receiving at least 65 Gy and 70 Gy. Thirteen patients receiving standard RT were compared with 10 DP patients. Toxicity was scored using CTCAE v3.0. Disease-related endpoints were locoregional control (LRC), disease-free survival (DFS) and overall survival (OS). Results: The mean composite toxicity score was maximal at the end of RT, with varying patterns across the CTCAE items. No significant difference in toxicity was found between the groups except for dysphagia at 6 months, where the standard RT group had worse scores (p=0.01). No differences were found in LRC and DFS. Two-year OS was 50% in the DP group versus 15% in the standard group (p=0.04), although this may reflect higher comorbidity in the standard group. Conclusion: DP of rsHNC did not increase toxicity compared with standard reirradiation. No evidence of improved disease control was found. However, DP may benefit selected patients, and future studies should focus on identifying these candidates. Clinical trial registration: https://clinicaltrials.gov , identifier NCT02921581.
SN - 2234-943X
ER -